We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
AYTU BioPharma Inc | NASDAQ:AYTU | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.81 | 2.60 | 2.99 | 0 | 09:00:00 |
FORM 3
|
Washington, D.C. 20549 |
OMB APPROVAL
OMB Number: 3235-0104 Estimated average burden hours per response... 0.5 |
|
|
|
1. Name and Address of Reporting Person * ARMISTICE CAPITAL, LLC |
2. Date of Event Requiring Statement (MM/DD/YYYY)
|
3. Issuer Name and Ticker or Trading Symbol AYTU BIOSCIENCE, INC [AYTU] |
|
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director
___
X
___ 10% Owner
_____ Officer (give title below) _____ Other (specify below) |
|
|
5. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Beneficially Owned |
|||
1.Title of Security
(Instr. 4) |
2. Amount of Securities Beneficially Owned
(Instr. 4) |
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) |
4. Nature of Indirect Beneficial Ownership
(Instr. 5) |
Common Stock, par value $.0001 | 2000000 | D (1) | |
Common Stock, par value $.0001 | 2000000 | I | See Footnote (2) |
Common Stock, par value $.0001 | 2000000 | I | See Footnote (2) |
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) |
|||||||
1. Title of Derivate Security
(Instr. 4) |
2. Date Exercisable and Expiration Date
(MM/DD/YYYY) |
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) |
4. Conversion or Exercise Price of Derivative Security |
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) |
6. Nature of Indirect Beneficial Ownership
(Instr. 5) |
||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Warrant | (3) | 3/6/2023 | Common Stock | 222222 | $10.80 | D (1) | |
Warrant | (3) | 3/6/2023 | Common Stock | 222222 | $10.80 | I | See Footnote (2) |
Warrant | (3) | 3/6/2023 | Common Stock | 222222 | $10.80 | I | See Footnote (2) |
Warrant | (3) | 3/23/2023 | Common Stock | 100000 | $10.80 | D (1) | |
Warrant | (3) | 3/23/2023 | Common Stock | 100000 | $10.80 | I | See Footnote (2) |
Warrant | (3) | 3/23/2023 | Common Stock | 100000 | $10.80 | I | See Footnote (2) |
Warrant | (3) | 10/9/2023 | Common Stock | 3907165 | $1.50 | D (1) | |
Warrant | (3) | 10/9/2023 | Common Stock | 3907165 | $1.50 | I | See Footnote (2) |
Warrant | (3) | 10/9/2023 | Common Stock | 3907165 | $1.50 | I | See Footnote (2) |
Reporting Owners
|
|||||
Reporting Owner Name / Address |
|
||||
Director | 10% Owner | Officer | Other | ||
ARMISTICE CAPITAL, LLC
510 MADISON AVENUE, 7TH FLOOR NEW YORK, NY 10022 |
|
X |
|
|
|
Armistice Capital Master Fund Ltd.
C/O DMS CORPORATE SERVICES LTD. 20 GENESIS CLOSE, P.O. BOX 314 GRAND CAYMAN, E9 KY1-1104 |
|
X |
|
|
|
Boyd Steven
C/O ARMISTICE CAPITAL, LLC 510 MADISON AVENUE, 7TH FLOOR NEW YORK, NY 10022 |
|
X |
|
|
Signatures
|
||
Armistice Capital, LLC By: /s/ Steven Boyd, Managing Member | 2/15/2019 | |
** Signature of Reporting Person | Date | |
Armistice Capital Master Fund Ltd. By: /s/ Steven Boyd, Director | 2/15/2019 | |
** Signature of Reporting Person | Date | |
/s/ Steven Boyd | 2/15/2019 | |
** Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year AYTU BioPharma Chart |
1 Month AYTU BioPharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions